NASDAQ: BVS
Bioventus Inc Stock Forecast, Predictions & Price Target

Analyst price target for BVS

Based on 2 analysts offering 12 month price targets for Bioventus Inc

Min Forecast
$15.00+22.15%
Avg Forecast
$16.00+30.29%
Max Forecast
$17.00+38.44%

Should I buy or sell BVS stock?

Based on 2 analysts offering ratings for Bioventus Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their BVS stock forecasts and price targets.

BVS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-11-06Find Out Why
lockedlocked$00.00+00.00%2024-09-27

1 of 1

Forecast return on equity

Is BVS forecast to generate an efficient return?

Company
30.01%
Industry
20.66%
Market
280.92%
BVS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BVS forecast to generate an efficient return on assets?

Company
5.8%
Industry
10.63%
BVS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BVS earnings per share forecast

What is BVS's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$0.41
Avg 2 year Forecast
$0.48
Avg 3 year Forecast
$0.55

BVS revenue forecast

What is BVS's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$564.2M+1.64%
Avg 2 year Forecast
$596.9M+7.54%
Avg 3 year Forecast
$628.5M+13.24%
BVS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BVS revenue growth forecast

How is BVS forecast to perform vs Medical Devices companies and vs the US market?

Company
3.67%
Industry
5.67%
Market
7.46%
BVS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BVS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BVS vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
BVS$12.28$16.00+30.29%Strong Buy
CBLL$28.02$31.50+12.42%Strong Buy
AVNS$19.60N/AN/A
CTKB$6.92$8.50+22.83%Strong Buy
FNA$10.32$13.33+29.20%Strong Buy

Bioventus Stock Forecast FAQ

Is Bioventus Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: BVS) stock is to Strong Buy BVS stock.

Out of 2 analysts, 1 (50%) are recommending BVS as a Strong Buy, 1 (50%) are recommending BVS as a Buy, 0 (0%) are recommending BVS as a Hold, 0 (0%) are recommending BVS as a Sell, and 0 (0%) are recommending BVS as a Strong Sell.

If you're new to stock investing, here's how to buy Bioventus stock.

What is BVS's earnings growth forecast for 2024-2026?

(NASDAQ: BVS) Bioventus's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 26.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.04%.

Bioventus's earnings in 2024 is -$39,482,000.On average, 1 Wall Street analyst forecast BVS's earnings for 2024 to be $33,273,372, with the lowest BVS earnings forecast at $33,273,372, and the highest BVS earnings forecast at $33,273,372. On average, 1 Wall Street analyst forecast BVS's earnings for 2025 to be $38,954,192, with the lowest BVS earnings forecast at $38,954,192, and the highest BVS earnings forecast at $38,954,192.

In 2026, BVS is forecast to generate $44,635,012 in earnings, with the lowest earnings forecast at $44,635,012 and the highest earnings forecast at $44,635,012.

What is BVS's revenue growth forecast for 2024-2026?

(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 3.67% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 5.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.46%.

Bioventus's revenue in 2024 is $555,061,000.On average, 1 Wall Street analysts forecast BVS's revenue for 2024 to be $45,786,432,847, with the lowest BVS revenue forecast at $45,786,432,847, and the highest BVS revenue forecast at $45,786,432,847. On average, 1 Wall Street analysts forecast BVS's revenue for 2025 to be $48,441,810,279, with the lowest BVS revenue forecast at $48,441,810,279, and the highest BVS revenue forecast at $48,441,810,279.

In 2026, BVS is forecast to generate $51,008,891,542 in revenue, with the lowest revenue forecast at $51,008,891,542 and the highest revenue forecast at $51,008,891,542.

What is BVS's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: BVS) forecast ROA is 5.8%, which is lower than the forecast US Medical Devices industry average of 10.63%.

What is BVS's Price Target?

According to 2 Wall Street analysts that have issued a 1 year BVS price target, the average BVS price target is $16.00, with the highest BVS stock price forecast at $17.00 and the lowest BVS stock price forecast at $15.00.

On average, Wall Street analysts predict that Bioventus's share price could reach $16.00 by Nov 6, 2025. The average Bioventus stock price prediction forecasts a potential upside of 30.29% from the current BVS share price of $12.28.

What is BVS's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: BVS) Bioventus's current Earnings Per Share (EPS) is -$0.60. On average, analysts forecast that BVS's EPS will be $0.41 for 2024, with the lowest EPS forecast at $0.41, and the highest EPS forecast at $0.41. On average, analysts forecast that BVS's EPS will be $0.48 for 2025, with the lowest EPS forecast at $0.48, and the highest EPS forecast at $0.48. In 2026, BVS's EPS is forecast to hit $0.55 (min: $0.55, max: $0.55).

What is BVS's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: BVS) forecast ROE is 30.01%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.